NewslettersHematopoiesis NewsRapamycin-Resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory, Multiple MyelomaBy Emily Salmini - January 29, 20250243This clinical trial evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma.[Journal for Immunotherapy of Cancer]Full Article